.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: RE42353

« Back to Dashboard

Claims for Patent: RE42353

Title:Quinazoline derivatives and pharmaceutical compositions containing them
Abstract: The invention relates to quinazoline derivatives of formula (1) ##STR00001## wherein m is an integer from 1 to 2; R.sup.1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkylthio, or --NR.sup.5R.sup.6 (wherein R.sup.5 and R.sup.6, which may be the same or different, each represents hydrogen or C.sub.1-3alkyl); R.sup.2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R.sup.3 represents hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X.sup.1 represents --O--, --CH.sub.2--, --S--, --SO--, --SO.sub.2--, --NR.sup.7CO--, --CONR.sup.8--, --SO.sub.2NR.sup.9--, --NR.sup.10SO.sub.2-- or --NR.sup.11-- (wherein R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 each independently represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl); R.sup.4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group selected from alkyl and a 5 or 6 membered saturated carbocyclic or heterocyclic group, and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
Inventor(s): Thomas; Andrew Peter (Macclesfield, GB), Johnstone; Craig (Macclesfield, GB), Clayton; Edward (Macclesfield, GB), Stokes; Elaine Sophie Elizabeth (Macclesfield, GB), Lohmann; Jean-Jacques Marcel (Reims Cedex, FR), Hennequin; Laurent Francois Andre (Reims Cedex, FR)
Assignee: AstraZeneca UK Limited (London, GB)
Application Number:12/170,027
Patent Claims: 1. A quinazoline derivative of the formula I: ##STR00027## wherein: m is an integer from 1 to 2; R.sup.1 represents hydrogen, hydroxy, halogeno, .[.nitro,.]. trifluoromethyl, cyano, C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkylthio, or --NR.sup.5R.sup.6 (wherein R.sup.5 and R.sup.6, which may be the same or different, each represents hydrogen or C.sub.1-3alkyl); R.sup.2 represents hydrogen, hydroxy, halogeno, methoxy.[.,.]. .Iadd.or .Iaddend.amino.[.or nitro.].; R.sup.3 represents hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X.sup.1 represents .[.--O--,.]. .Iadd.--O--;.Iaddend. R.sup.4 is selected from one of the following eleven groups: 1) C.sub.1-5alkylR.sup.12 (wherein R.sup.12 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to C.sub.1-5alkyl through a carbon atom and which heterocyclic group may bear one or two .[.substituent.]. .Iadd.substituents .Iaddend.selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl, C.sub.1-4alkoxy, carbamoyl, C.sub.1-4alkylcarbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, C.sub.1-4alkanoyl and C.sub.1-4alkoxycarbonyl) or C.sub.1-5alkylR.sup.13 (wherein R.sup.13 is a group selected from pyrrolidin-1-yl, imidazolidin-1-yl and thiomorpholino, which group may bear one or two .[.substituent.]. .Iadd.substituents .Iaddend.selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl, C.sub.1-4alkoxy, carbamoyl, C.sub.1-4alkylcarbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, C.sub.1-4alkanoyl and C.sub.1-4alkoxycarbonyl); 2) C.sub.2-5alkenylR.sup.14 (wherein R.sup.14 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two .[.substituent.]. .Iadd.substituents .Iaddend.selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl, C.sub.1-4alkoxy, carbamoyl, C.sub.1-4alkylcarbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, C.sub.1-4alkanoyl and C.sub.1-4alkoxycarbonyl); 3) C.sub.3-5alkynylR.sup.15 (wherein R.sup.15 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two .[.substituent.]. .Iadd.substituents .Iaddend.selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl, C.sub.1-4alkoxy, carbamoyl, C.sub.1-4alkylcarbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, C.sub.1-4alkanoyl and C.sub.1-4alkoxycarbonyl); 4) C.sub.1-5alkylX.sup.2C.sub.1-5alkylX.sup.3R.sup.16 (wherein X.sup.2 and X.sup.3 which may be the same or different are each --O--, --S--, --SO--, --SO.sub.2--, --NR.sup.17CO--, --CONR.sup.18--, --SO.sub.2NR.sup.19--, --NR.sup.20SO.sub.2-- or --NR.sup.21-- (wherein R.sup.17, R.sup.18, R.sup.19, R.sup.20 and R.sup.21 each independently represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) and R.sup.16 represents hydrogen or C.sub.1-3alkyl); 5) C.sub.1-5alkylX.sup.4COR.sup.22 (wherein X.sup.4 represents --O-- or --NR.sup.23-- (wherein R.sup.23 represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) and R.sup.22 represents --NR.sup.24R.sup.25 or --OR.sup.26 (wherein R.sup.24, R.sup.25 and R.sup.26 which may be the same or different each represents hydrogen, C.sub.1-4alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl)); 6) C.sub.1-5alkylX.sup.5R.sup.27 (wherein X.sup.5 represents --O--, --S--, --SO--, --SO.sub.2--, --OCO--, --NR.sup.28CO--, --CONR.sup.29--, --SO.sub.2NR.sup.30--, --NR.sup.31SO.sub.2-- or --NR.sup.32-- (wherein R.sup.28, R.sup.29, R.sup.30, R.sup.31 and R.sup.32 each independently represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) or X.sup.5 is carbonyl, and R.sup.27 represents cyclopentyl, cyclohexyl or a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which cyclopentyl, cyclohexyl or heterocyclic group may bear one or two .[.substituent.]. .Iadd.substituents .Iaddend.selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl, C.sub.1-4alkoxy, carbamoyl, C.sub.1-4alkylcarbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, C.sub.1-4alkanoyl and C.sub.1-4alkoxycarbonyl or R.sup.27 is .[.C.sub.1-3allyl.]. .Iadd.C.sub.1-3alkyl .Iaddend.with the proviso that when R.sup.27 is C.sub.1-3alkyl, X.sup.5 is --S--, --SO--, --SO.sub.2--, --SO.sub.2NR.sup.30-- .[.or --NR.sup.31SO.sub.2--.]. .Iadd.or --NR.sup.31SO.sub.2--).Iaddend.; 7) C.sub.1-3alkoxyC.sub.2-4alkyl or C.sub.1-4alkyl; 8) C.sub.1-5alkylX.sup.6C.sub.1-5alkylR.sup.33 (wherein X.sup.6 represents --O--, --S--, --SO--, --SO.sub.2--, --NR.sup.34CO--, --CONR.sup.35--, --SO.sub.2NR.sup.36--, --NR.sup.37SO.sub.2-- or --NR.sup.38-- (wherein R.sup.34, R.sup.35, R.sup.36, R.sup.37 and R.sup.38 each independently represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) and R.sup.33 represents cyclopentyl, cyclohexyl or a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which cyclopentyl, cyclohexyl or heterocyclic group may bear one or two .[.substitutes.]. .Iadd.substituents .Iaddend.selected from oxo, hydroxy, halogeno, .[.C.sub.1-4alkyl),.]. .Iadd.C.sub.1-4alkyl, .Iaddend.C.sub.1-4hydroxyalkyl, C.sub.1-4alkoxy, carbamoyl, C.sub.1-4alkylcarbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, C.sub.1-4alkanoyl and C.sub.1-4alkoxycarbonyl); 9) R.sup.39 (wherein R.sup.39 is a group selected from pyrrolidin-3-yl, .[.piperidine-3-yl and piperidine-4-yl.]. .Iadd.piperidin-3-yl and piperidin-4-yl .Iaddend.which group may bear one or two .[.substituent.]. .Iadd.substituents .Iaddend.selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl, C.sub.1-4alkoxy, carbamoyl, C.sub.1-4alkylcarbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, C.sub.1-4alkanoyl and C.sub.1-4alkoxycarbonyl); 10) C.sub.1-5alkylR.sup.40 (wherein R.sup.40 is piperazin-1-yl which bears at least one substituent selected from C.sub.1-4alkanoyl, C.sub.1-4alkoxycarbonyl, C.sub.1-4hydroxyalkyl and --CONR.sup.41R.sup.42 (wherein R.sup.41 and R.sup.42 each independently represents hydrogen .[.or C.sub.1-4alkyl).]. .Iadd.or C.sub.1-4alkyl)).Iaddend.; and 11) C.sub.1-5alkylR.sup.44 (wherein R.sup.44 is morpholino which bears at least one and optionally two .[.substituent.]. .Iadd.substituents .Iaddend.selected from oxo, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl, carbamoyl, C.sub.1-4alkylcarbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, C.sub.1-4alkanoyl and C.sub.1-4alkoxycarbonyl); with the further proviso that when R.sup.4 is selected from group 7) .[.R.sup.1 and/or R.sup.2 is/are nitro or.]. at least one R.sup.3 is C.sub.1-3alkanoyloxy; or a salt thereof.

2. A quinazoline derivative as claimed in claim 1 wherein R.sup.1 represents hydrogen, hydroxy, cyano, .[.nitro,.]. trifluoromethyl, methyl, ethyl, methoxy or ethoxy.

3. A quinazoline derivative as claimed in claim 1 or claim 2 wherein R.sup.2 is hydrogen.

4. A quinazoline derivative as claimed in claim 1 or claim 2 wherein the phenyl group bearing (R.sup.3).sub.m is of the formula II: ##STR00028## wherein: R.sup.a represents hydrogen, methyl, fluoro, or chloro; R.sup.b represents hydrogen, methyl, methoxy, bromo, fluoro or chloro; R.sup.c represents hydrogen or hydroxy; R.sup.d represents hydrogen, fluoro or chloro.

5. A quinazoline derivative as claimed in claim 1 or claim 2 wherein R.sup.4 is selected from one of the following nine groups: 1) C.sub.1-4alkylR.sup.12 (wherein R.sup.12 is a group selected from 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, .[.piperidine-2-yl, piperidine-3-yl, piperidine-4-yl,.]. .Iadd.piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, .Iaddend.morpholin-2-yl, morpholin-3-yl and piperazin-2-yl which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl) or C.sub.2-4alkylR.sup.45 (wherein R.sup.45 is a group selected from .[.imidazolidine-1-yl,.]. .Iadd.imidazolidin-1-yl, .Iaddend.pyrrolidin-1-yl and thiomorpholino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl); 2) 1-R.sup.46prop-1-en-3-yl, 1-R.sup.46but-2-en-4-yl, .[.1-but-1-en-3-yl,.]. .Iadd.1-R.sup.46but-1-en-3-yl, .Iaddend.1-R.sup.46pent-2-en-4-yl or 2-R.sup.46pent-3-en-5yl (wherein R.sup.46 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a carbon atom and which heterocyclic group may bear one or two .[.substituent.]. .Iadd.substituents .Iaddend.selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl) or 1-R.sup.47but-2-en-4-yl, 1-R.sup.47pent-2-en-4-yl or 2-R.sup.47pent-3-en-5-yl (wherein R.sup.47 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl); 3) 1-R.sup.48prop-1-yn-3-yl, 1-R.sup.48but-2-yn-4-yl, 1-R.sup.48but-1-yn-3-yl, 1-R.sup.48pent-2-yn-4-yl or 2-R.sup.48pent-3-yn-5-yl (wherein R.sup.48 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl) or 1-R.sup.49but-2-yn-4-yl, 1-R.sup.49pent-2-yn-4-yl or 2-R.sup.49pent-3-yn-5-yl (wherein R.sup.49 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkylcarbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl); 4) C.sub.2-3alkylX.sup.2C.sub.1-3alkylX.sup.3R.sup.16 (wherein X.sup.2 and X.sup.3 are as defined in claim 1 and R.sup.16 represents hydrogen or C.sub.1-3alkyl); 5) C.sub.2-3alkylX.sup.4COR.sup.22 (wherein X.sup.4 is as defined in claim 1 and R.sup.22 represents --NR.sup.24R.sup.25 or --OR.sup.26 (wherein R.sup.24, R.sup.25 and R.sup.26 which may be the same or different each represents hydrogen, C.sub.1-4alkyl or C.sub.1-2alkoxyethyl)); 6) C.sub.2-3alkylX.sup.5R.sup.27 (wherein X.sup.5 is as defined in claim 1 and R.sup.27 represents a group selected from cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl which group is linked to X.sup.5 through a carbon atom and which group may carry one substituent selected from oxo, hydroxy, halogeno, C.sub.1-2alkyl, C.sub.1-2hydroxyalkyl, C.sub.1-2alkoxy, carbamoyl, C.sub.1-2alkylcarbamoyl, N,N-di(C.sub.1-2alkyl)carbamoyl, acetyl and C.sub.1-2alkoxycarbonyl or R.sup.27 is C.sub.1-3alkyl with the proviso that when R.sup.27 is C.sub.1-3alkyl, X.sup.5 is --S--, --SO--, --SO.sub.2--, --SO.sub.2N.sup.30-- or --NR.sup.31SO.sub.2--); 7) C.sub.2-3alkylX.sup.6C.sub.2-3alkyl.sup.33 (wherein X.sup.6 is as defined in claim 1 and R.sup.33 represents a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two .[.substituent.]. .Iadd.substituents .Iaddend.selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl, and C.sub.1-3alkoxycarbonyl); 8) C.sub.2-3alkylR.sup.40 .Iadd.(wherein R.sup.40 .Iaddend.is piperazin-1-yl which bears at least one substituent selected from acetyl, C.sub.1-2alkoxycarbonyl, C.sub.1-2hydroxyalkyl and CONR.sup.41R.sup.42 (wherein R.sup.41 and R.sup.42 each independently represents hydrogen .[.or C.sub.1-2alkyl).]. .Iadd.or C.sub.1-2alkyl)).Iaddend.; and 9) C.sub.2-3alkylR.sup.44 .Iadd.(wherein R.sup.44 .Iaddend.is morpholino which bears at least one and optionally two substituents selected from oxo, .[.C.sub.1-2alky,.]. .Iadd.C.sub.1-2alkyl, .Iaddend.C.sub.1-2hydroxyalkyl, carbamoyl, C.sub.1-2alkylcarbamoyl, N,N-di(C.sub.1-2alkyl)carbamoyl, .[.acaetyl.]. .Iadd.acetyl .Iaddend.and C.sub.1-2alkoxycarbonyl).

6. A quinazoline derivative as claimed in claim 5 wherein R.sup.4 is selected from one of the following seven groups: 1) .[.C.sub.1-3alkylR.sup.12.]. .Iadd.C.sub.1-3alkylR.sup.12 .Iaddend.(wherein R.sup.12 is a group selected from 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl and piperazin-2-yl which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-2alkyl, C.sub.1-2hydroxyalkyl, C.sub.1-2alkoxy, carbamoyl, C.sub.1-2alkylcarbamoyl, N,N-di(C.sub.1-2alkyl)carbamoyl, acetyl and C.sub.1-2alkoxycarbonyl) or C.sub.2-3alkylR.sup.45 (wherein R.sup.45 is a group selected from imidazolidin-1-yl, pyrrolidin-1-yl and thiomorpholino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-2alkyl, C.sub.1-2hydroxyalkyl, C.sub.1-2alkoxy, carbamoyl, C.sub.1-2alkylkcarbamoyl, N,N-di(C.sub.1-2alkyl)carbamoyl, acetyl and C.sub.1-2alkoxycarbonyl); 2) 1-R.sup.50but-2-en-4-yl (wherein R.sup.50 is a group selected from imidazolidin-1-yl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, piperidin-4-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperazin-1-yl, morpholino, thiomorpholino and piperidino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-2alkyl, C.sub.1-2hydroxyalkyl, C.sub.1-2alkoxy, carbamoyl, C.sub.1-2alkylcarbamoyl, N,N-di(C.sub.1-2alkyl)carbamoyl, acetyl and C.sub.1-2alkoxycarbonyl). 3) 1-R.sup.51but-2-yn-4-yl (wherein R.sup.51 is a group selected from imidazolidin-1-yl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, piperidin-4-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperazin-1-yl morpholino, thiomorpholino and piperidino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-2alkyl, C.sub.1-2hydroxyalkyl, C.sub.1-2alkoxy, carbamoyl, C.sub.1-2alkylcarbamoyl, N,N-di(C.sub.1-2alkyl)carbamoyl, acetyl and C.sub.1-2alkoxycarbonyl); 4) C.sub.2-3alkylX.sup.2C.sub.1-3alkylX.sup.3R.sup.16 (wherein X.sup.2 and X.sup.3 are as defined in claim 1 and R.sup.16 represents hydrogen or C.sub.1-3alkyl); 5) 2-(3,3-dimethylureido)ethyl, .[.3-(3,3dimethylureido)propyl,.]. .Iadd.3-(3,3-dimethylureido)propyl, .Iaddend.2-(3-methylureido)ethyl, 3-(3-methylureido)propyl, 2-ureidoethyl, 3-ureidopropyl, 2-(N,N-dimethylcarbamoyloxy)ethyl, 3-(N,N-dimethylcarbamoyloxy)propyl, 2-(N-methylcarbamoyloxy)ethyl, 3-(N-methylcarbamoyloxy)propyl, 2-(carbamoyloxy)ethyl, 3-(carbamoyloxy)propyl, 2-(1,3,3-trimethylureido)ethyl, .[.3-1,3,3-trimethylureido)propyl,.]. .Iadd.3-(1,3,3-trimethylureido)propyl, .Iaddend.2-(isopropoxycarbonylamino)ethyl, 3-(isopropoxycarbonylamino)propyl, 2-(isobutoxycarbonylamino)ethyl, 3-(isobutoxycarbonylamino)propyl, 2-(t-butoxycarbonylamino)ethyl or 3-(t-butoxycarbonylamino)propyl; 6) C.sub.2-3alkylX.sup.5R.sup.27 (wherein R.sup.27 is C.sub.1-2alkyl and X.sup.5 is --S--, --SO--, --SO.sub.2--, --SO.sub.2NR.sup.30-- .[.or --NR.sup.31 SO.sub.2--.]. .Iadd.or --NR.sup.31SO.sub.2--).Iaddend.; and 7) C.sub.2-3alkyX.sup.6C.sub.2-3alkylR.sup.33 (wherein X.sup.6 is as defined in claim 1 and R.sup.33 represents a group selected from morpholino, 2-oxopyrrolidin-1-yl, pyrrolidin-1-yl, piperidino, piperazin-1-yl and 4-methylpiperazin-1-yl).

7. A quinazoline derivative of the formula 1a: ##STR00029## wherein: R.sup.1a is hydrogen or methoxy; R.sup.2a is hydrogen; the phenyl group bearing (R.sup.3a).sub.ma is the 4-chloro-2-fluorophenyl group or the 4-bromo-2-fluorophenyl group; X.sup.1a is --O--; R.sup.4a is selected from one of the following nine groups: 1) C.sub.1-4alkylR.sup.7a (wherein R.sup.7a is a group selected from 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl and piperazin-2-yl which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl) or C.sub.2-4alkylR.sup.8a (wherein R.sup.8a is a group selected from imidazolidin-1-yl, pyrrolidin-1-yl and thiomorpholino which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl); 2) 1-R.sup.9aprop-1-en-3-yl, 1-R.sup.9abut-2-en-4-yl, 1-R.sup.9abut-1-en-3-yl, 1-R.sup.9apent-2-en-4-yl or 2-R.sup.9apent-3-en-5-yl (wherein R.sup.9a is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl) or 1-R.sup.10abut-2-en-4-yl, 1-R.sup.10apent-2-en-4-yl or 2-R.sup.10apent-3-en-5-yl (wherein R.sup.10a is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkenyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbomoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.1-3alkanoyl and C.sub.1-3alkoxycarbonyl); 3) 1-R.sup.11aprop-1-yn-3-yl, 1-R.sup.11abut-2-yn-4-yl, 1-R.sup.11abut-1-yn-3-yl, 1-R.sup.11apent-2-yn-4-yl or 2-R.sup.11apent-3-yn-5-yl (wherein R.sup.11a is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl and C.sub.1-3alkoxycarbonyl) or 1-R.sup.12abut-2-yn-4-yl, .[.1-.sup.12apent-2-yn-4-yl.]. .Iadd.1-R.sup.12apent-2-yn-4-yl .Iaddend.or 2-R.sup.12apent-3-yn-5-yl (wherein R.sup.12a is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, of which one is N and the other is selected independently from O, S and N, which heterocyclic group is linked to the alkynyl group through a nitrogen atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, .[.carbarmoyl,.]. .Iadd.carbamoyl, .Iaddend.C.sub.1-3alkylcarbamoyl, .[.N,N-di(C.sub.1-3alkyl)carbarmoyl, C.sub.1-3alkanoyl.]. .Iadd.N,N-di(C.sub.1-3alkyl)carbamoyl, C.sub.2-3alkanoyl .Iaddend.and C.sub.1-3alkoxycarbonyl); 4) C.sub.2-3alkylX.sup.2aC.sub.1-3alkylX.sup.3aR.sup.13a (wherein X.sup.2a and X.sup.3a which may be the same or different each represents, --O--, --S--, --SO--, --SO.sub.2--, --NR.sup.14aCO--, or --NR.sup.15a-- (wherein R.sup.14a and R.sup.15a each independently represents hydrogen, C.sub.1-2alkyl or C.sub.1-2alkoxyethyl) and R.sup.13a represents hydrogen or C.sub.1-3alkyl); 5) .[.C2-3alkylX.sup.4aCOR.sup.16a.]. .Iadd.C.sub.2-3alkylX.sup.4aCOR.sup.16a .Iaddend.(wherein X.sup.4a represents --O-- or --NR.sup.17a--(wherein R.sup.17a represents hydrogen, C.sub.1-3alkyl or C.sub.1-2alkoxyethyl) and R.sup.16a represents --NR.sup.18aR.sup.19a or --OR.sup.20a (wherein R.sup.18a, R.sup.19a and R.sup.20a which may be the same or different each represents hydrogen, C.sub.1-4alkyl or C.sub.1-2alkoxyethyl)); 6) C.sub.2-3alkylX.sup.5aR.sup.21a (wherein X.sup.5a represents carbonyl, --O--, --S--, --SO--, --SO.sub.2--, --NR.sup.22aCO--, --NR.sup.23aSO.sub.2--, or --NR.sup.24a-- (wherein R.sup.22a, R.sup.23a and .[.R.sup.23a each independently.]. .Iadd.R.sup.24a each independently .Iaddend.represents hydrogen, C.sub.1-2alkyl or C.sub.1-2alkoxyethyl) and R.sup.21a represents a group selected from cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl which group is linked to X.sup.5a through a carbon atom and which group may carry one substituent selected from oxo, hydroxy, halogeno, C.sub.1-2alkyl, C.sub.1-2hydroxyalkyl, C.sub.1-2alkoxy, carbamoyl, C.sub.1-2alkylcarbamoyl, N,N-di(C.sub.1-2alkyl)carbamoyl, acetyl and C.sub.1-2alkoxycarbonyl or R.sup.21a is C.sub.1-3alkyl with .[.that proviso.]. .Iadd.the proviso .Iaddend.that when R.sup.21a is C.sub.1-3alkyl, X.sup.5a is --S--, --SO--, --SO.sub.2-- or --NR.sup.23aSO.sub.2--); 7) C.sub.2-3alkylX.sup.6aC.sub.2-3alkylR.sup.25a (wherein X.sup.6a represents --O--, --S--, --SO--, --SO.sub.2--, --NR.sup.26aCO--, --NR.sup.27aSO.sub.2-- or --NR.sup.28a-(wherein R.sup.26a, R.sup.27a and R.sup.28a each independently represents hydrogen, C.sub.1-2alkyl or C.sub.1-2alkoxyethyl) and R.sup.25a represents a 5 or 6 membered saturated heterocyclic group with one or two heteratoms selected independently from O, S and N, which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3hydroxyalkyl, C.sub.1-3alkoxy, carbamoyl, C.sub.1-3alkylcarbamoyl, .[.N,N-di(C.sub.1-3alkyl)cabamoyl,.]. .Iadd.N,N-di(C.sub.1-3alkyl)carbamoyl, .Iaddend.C.sub.2-3alkanoyl, and .[.C1-3allkoxycarbonyl);.]. .Iadd.C.sub.1-3alkoxycarbonyl);.Iaddend. 8) C.sub.2-3alkylR.sup.29a (wherein R.sup.29a is .[.piperizin-1-yl.]. .Iadd.piperazin-1-yl .Iaddend.which bears at least one substituent selected from acetyl, C.sub.1-2alkoxycarbonyl, C.sub.1-2hydroxyalkyl and CONR.sup.30aR.sup.31a (wherein R.sup.30a and R.sup.31a each independently represents hydrogen .[.or C.sub.1-2alkyl).]. .Iadd.or C.sub.1-2alkyl)).Iaddend.; and 9) C.sub.2-3alkylR.sup.33a (wherein R.sup.33a is morpholino which bears at least one and optionally two substituents selected from oxo, C.sub.1-2alkyl, C.sub.1-2hydroxyalkyl, carbamoyl, C.sub.1-2alkylcarbamoyl, N,N-di(C.sub.1-2alkyl)carbamoyl, acetyl and C.sub.1-2alkoxycarbonyl); or a salt thereof.

.[.8. A quinazoline derivative as claimed in claim 1 selected from: 4-(4-chloro-2-fluoroanilino)-7-(1,3-dioxolan-2-ylmethoxy)-6-methoxyquinzo- line; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(4-morpholinobut-2-en-1-ylo- xy)quinazoline; (E)-4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(4-morpholinobut-2-en-1-ylox- y)-quinazoline; 4-(4-chloro-2-fluoroanilino)-7-(3-(2,6-dimethylmorpholino)propoxy)-6-meth- oxyquinazoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-([N-methyl-N-methylsulphonyl]- amino)-propoxy)quinazoline; 7-(2-[N-tert-butoxycarbonylamino]ethoxy)-4-(4-chloro-2-fluoroanilino)-6-m- ethoxyquinazoline; 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-([N-methyl-N-methylsulphonyl]a- mino)-propoxy)quinazoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-2-(2-oxoimidazolidin-1-yl)ethoxy- )quinazoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(3-oxomorpholino)ethoxy)quina- zoline; 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(3-oxomorpholino)ethoxy- )quinazoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-thiomorpholinoethoxy)quinazol- ine; (S)-4-(4-bromo-2-fluoroanilino)-7-(3-(2-carbamoylpyrrolidin-1-yl)prop- oxy-6-methoxyquinazoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(2-oxopyrrolidin-1-yl)propoxy- )quinazoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-oxopyrrolidin-1-yl)ethoxy)- -quinazoline; (S)-7-(3-(2-carbamoylpyrrolidin-1-yl)propoxy)-4-(4-chloro-2-fluoroanilino- )-6-methoxyquinazoline, 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-morpholinoethoxy)ethoxy)-q- uinazoline; and 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(3-(2-oxopyrrolidin-1-yl)propoxy)- -quinazoline; and salts thereof..].

.[.9. A quinazoline derivative as claimed in claim 1 selected from: 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)quina- zoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-3-yl)-- methoxyquinazoline; 4-(4-bromo-2-fluoroanilino)-7-3-(1,1-dixothiomorpholino)propoxy)-6-methox- yquinazoline; 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)quinaz- oline, 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-2-pyrrolidin-1-ylethoxy- )ethoxy)-quinazoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-[4-methylpiperazin-1-yl]et- hoxy)-ethoxy)quinazoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-([N-methyl-N-methoxyacetyl]am- ino)-ethoxy)quinazoline; and 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-2-oxopyrrolidin-1-yl)ethoxy)qu- inazoline; and salts thereof..].

.[.10. A quinazoline derivative as claimed in claim 1 selected from: (E)-4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(4-(pyrrolidin-1-yl)but-2-en- -1-yloxy)-quinazoline; 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(methylsulphonyl)propoxy)quin- azoline; (S)-4-4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-3-- yl)-methoxyquinazoline; and (R)-4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-3-yl)-met- hoxyquinazoline; and salts thereof..].

.[.11. A quinazoline derivative as claimed in claim 1 selected from: 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(methylsulphonyl)propoxy)quin- azoline; and salts thereof..].

12. A quinazoline derivative as claimed in .[.any one of claims 1 and 7-11.]. .Iadd.claim 1 or claim 7 .Iaddend.in the form of pharmaceutically acceptable salt.

13. A quinazoline derivative as claimed in claim 1 or claim 2 wherein R.sup.1 represents methoxy.

14. A quinazoline derivative as claimed in claim 1 or claim 2 wherein m is 2.

15. A quinazoline derivative as claimed in claim 1 or claim 2 wherein the phenyl group bearing (R.sup.3)m is the 4-chloro-2-fluorophenyl group or the 4-bromo-2-fluorophenyl group.

16. A quinazoline derivative as claimed in claim 1 or claim 2 wherein R.sup.4 is selected from one of the following six groups: 1) C.sub.1-3alkylR.sup.12 (wherein R.sup.12 is 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3dithiolan-2-yl, 1,3-dithian-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 1-methylpiperidin-2-yl, 1-methylpiperidin-3-yl, 1-methylpiperidin-4- yl, 1-methylpyrrolidin-2-yl, 1-methylpyrrolidin-3-yl, piperazin-2-yl, 1-methylpiperazine-2-yl, 4-methylpiperazin-2-yl, 1,4-dimethylpiperazin-2-yl, morpholin-2-yl, morpholin-3-yl, 4-methylmorpholin-2-yl or 4-methylmorpholin-3- yl) or C.sub.2-3alkylR.sup.45 (wherein R.sup.45 is pyrrolidin-1-yl, thiomorpholino, 1,1- dioxothiomorpholino, 2-oxopyrrolidin-1-yl, 2-(N-methylcarbamoyl)pyrrolidin-1-yl, 2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl, 2-carbamoylpyrrolidin-1yl, 2- oxoimidazolidin-1-yl or 3-methyl-2-oxoimidazolidin-1-yl); 2) 1-R.sup.50but-2-en-4-yl (wherein R.sup.50 is 2-oxoimidazolidin-1-yl, 1,3-dioxolan-2-yl, 1,3- dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, piperidin-4-yl, 1-methylpiperidin-4- yl, pyrrolidin-1-yl, 1-methylpyrrolidin-3-yl, piperazin-1-yl, morpholino, thiomorpholino, 4-methylpiperazin-1-yl, piperidino or 3-methyl-2-oxoimidazolidin- 1-yl); 3) 1-R.sup.51but-2-yn-4-yl (wherein R.sup.51 is 2-oxoimidazolidin-1-yl, 1,3-dioxolan-2-yl, 1,3- dioxan-2-yl, 1,3-dithiolan-2-yl, 1,3-dithian-2-yl, piperidin-4-yl, 1-methylpiperidin-4- yl, pyrrolidin-1-yl, 1-methylpyrrolidin-3-yl, piperazin-1-yl, morpholino, thiomorpholino, 4-methylpiperazin-1-yl, piperidino or 3-methyl-2-oxoimidazolidin- 1-yl); 4) C.sub.2-3alkylX.sup.2C.sub.1-3alkylX.sup.3R.sup.16 (wherein X.sup.2 and X.sup.3 are as defined in claim 17 and R.sup.16 represents hydrogen or C.sub.1-3alkyl); 5) C.sub.2-3alkylX.sup.5R.sup.27 (wherein R.sup.27 is C.sub.1-2 alkyl and X.sup.5 is -S-, -SO-, -SO.sub.2-, -SO.sub.2NR.sup.30-or- NR.sup.31SO.sub.2-(wherein R.sup.30 and R.sup.31 are as defined in claim 1)); and 6) C.sub.2-3alkylX.sup.6C.sub.2-3alkylR.sup.33 (wherein X.sup.6 is as defined in claim 1 and R.sup.33 represents a group selected from pyrrolidin-1-yl, 4-methylpiperazin-1-yl and morpholino).

17. A quinazoline derivative of the formula I: ##STR00030## wherein: m is an integer from 1 to 2; R.sup.1 represents hydrogen, hydroxy, halogeno, .[.nitro,.]. trifuloromethyl, .[.eyano,.]. .Iadd.cyano, .Iaddend.C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkylthio, or -NR.sup.5R.sup.6 (wherein R.sup.5and R.sup.6, which may be the same or different, each represents hydrogen or C.sub.1-3alkyl); .[.R.sub.2.]. .Iadd.R.sup.2 .Iaddend.represents hydrogen, hydroxy, .[.halageno,.]. .Iadd.halogeno, .Iaddend.methoxy.[.,.]. .Iadd.or .Iaddend.amino.[.or nitro.].; .[.R.sub.3.]. .Iadd.R.sup.3 .Iaddend.represents hydroxy, halogeno, C.sub.1-3alkyl, C.sub.1-3alkoxy, C.sub.1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X.sup.1 represents -O-; R.sup.4 is selected from one of the following seven groups: 1) C.sub.1-5alkylR.sup.12 (wherein R.sup.12 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group is linked to C.sub.1-5alkyl through a carbon atom and which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy) or C.sub.1-5alkylR.sup.13 (wherein R.sup.13 is a group selected from pyrrolidin-1-yl, imidazolidin-1-yl and thiomorpholino, which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy); 2) .[.C.sub.2-5alkenylR.sup.14.]. .Iadd.C.sub.2-5alkenylR.sup.14 .Iaddend.(wherein R.sup.14 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, .[.C.sub.1-4hydroyalkyl.]. .Iadd.C.sub.1-4hydroxyalkyl .Iaddend.and C.sub.1-4alkoxy); 3) C.sub.2-5alkynylR.sup.15 (wherein R.sup.15 is a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or two substituents selected from oxo, hydroxy halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy); 4) C.sub.1-5alkylX.sup.2C.sub.1-5alkylX.sup.3R.sup.16 (wherein X.sup.2 and X.sup.3 which may be the same or different are each -O-, -S-, -SO-, -SO.sub.2-, -NR.sup.17CO-, -CONR.sup.18-, .[..sup.-SO.sub.2NR.sup.19-, -NR.sup.20SO.sub.2-.]. .Iadd.--SO.sub.2NR.sup.19--, --NR.sup.20SO.sub.2-- .Iaddend.or -NR.sup.21- (wherein R.sup.17, R.sup.18, R.sup.19, R.sup.20 and R.sup.21 each .[.independetly.]. .Iadd.independently .Iaddend.represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) and R.sup.16 represents hydrogen or C.sub.1-3alkyl); 5) C.sub.1-5alkylX.sup.4COR.sup.22 (wherein X.sup.4 represents -O- or -NR.sup.23-(wherein R.sup.23 represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) and R.sup.22 represents -NR.sup.24R.sup.25 or -OR.sup.26 (wherein R.sup.24, R.sup.25 and R.sup.26 which may be the same or different each represents hydrogen, C.sub.1-4alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl)); 6) C.sub.1-5alkylX.sup.5R.sup.27 (wherein X.sup.5 represents -O-, -S-, -SO.sub.2-, -OCO-, -NR.sup.28CO-, -CONR.sup.29-, -SO.sub.2NR.sup.30-, -NR.sup.31SO.sub.2- or -NR.sup.32-(wherein R.sup.28, R.sup.29, R.sup.30, R.sup.31 and R.sup.32 each independently represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) and R.sup.27 represents cyclopentyl, cyclohexyl or a 5 or 6 membered saturated heterocyclic group with one or two heteroatoms, selected independently from O, S and N, which cyclopentyl, cyclohexyl or heterocyclic group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl .[.and C.sub.1-4alkoxy.]. .Iadd.and C.sub.1-4alkoxy).Iaddend.; and 7) C.sub.1-3alkoxyC.sub.2-4alkyl or C.sub.1-4alkyl; with the proviso that when R.sup.4 is selected from group 7) .[.R.sup.1 and/or R.sup.2 is/are nitro or.]. at least one R.sup.3 is C.sub.1-3alkanoyloxy; and salts thereof.

18. A quinazoline derivative as claimed in claim 17 wherein R.sup.1 represents methoxy.

19. A quinazoline derivative as claimed in 17 or claim 18 wherein R.sup.2 represents hydrogen.

20. A quinazoline derivative as claimed in claim 17 or claim 18 wherein the phenyl group bearing (R.sup.3)m is of the formula II: ##STR00031## wherein: R.sup.a represents hydrogen, methyl, fluoro or chloro; R.sup.b represents hydrogen, methyl, methoxy, bromo, fluoro or chloro; R.sup.c represents hydrogen or hydroxy; R.sup.d represents hydrogen, fluoro or chloro.

21. A process for the preparation of a quinazoline derivative of formula I or salt thereof (as defined in claim 1) which comprises: (a) the reaction of a compound of the formula III: ##STR00032## (wherein R.sup.1, R.sup.2, X.sup.1 and R.sup.4 are as defined in claim 1 and L.sup.1 is a displaceble moiety), with a compound of the formula IV: ##STR00033## (wherein R.sup.3 and m are as defined in claim 1) whereby to obtain compounds of the formula I and salts thereof; (b) for the .[.preperation.]. .Iadd.preparation .Iaddend.of compounds of formula I and salts thereof in which the group of formula IIa: ##STR00034## (wherein R.sup.3 and m are as defined in claim 1) represents a phenyl group carrying one or more hydroxy groups, the deprotection of a compound of formula V: ##STR00035## (wherein X.sup.1, m, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined in claim 1, P represents a phenolic hydroxy protecting group and p1 is an integer from 1 to 5 equal to the number of protected hydroxy groups and such that m-p1 is equal to the number of R.sup.3 substituents which are not protected hydroxy); (c) for the preparation of those compounds of formula I and salts thereof wherein the substituent X.sup.1 is --O--, the reaction of a compound of the formula VI: ##STR00036## (wherein X.sup.1, R.sup.1, R.sup.2 and R.sup.3 are as defined in claim 1) with a compound of formula VII: R.sup.4--L.sup.1 (VII) (wherein .[.R.sup.14.]. .Iadd.R.sup.4 .Iaddend.is as defined .[.im.]. .Iadd.in .Iaddend.claim 1 and L.sup.1 is as defined herein); (d) the reaction of a compound of the formula VII: ##STR00037## with a compound of the formula IX: R.sup.4--X.sup.1--H (IX) (wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, m and X.sup.1 are as defined in claim 1 and L.sup.1 is as defined herein); (e) for the preparation of compounds of formula I and salts thereof wherein R.sup.4 is C.sub.1-5alkylR.sup.53, wherein R.sup.53 is selected from one of the following three groups: 1) X.sup.7R.sup.27 (wherein X.sup.7 represents --O--, --S--, --SO.sub.2--, --NR.sup.54CO--, --NR.sup.55SO.sub.2-- or --NR.sup.56-- (wherein R.sup.54, R.sup.55 and R.sup.56 each independently represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) and R.sup.27 is as defined in claim 1); 2) X.sup.8C.sub.1-5alkylX.sup.3R.sup.16 (wherein X.sup.8 represents --O--, --S--, .[.--SO.sub.12--,.]. .Iadd.--SO.sub.2--, .Iaddend.--NR.sup.57CO--, --NR.sup.58SO.sub.2-- or --NR.sup.59-- (wherein R.sup.57, R.sup.58 and R.sup.59 each independently represents hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) and X.sup.3 and R.sup.16 are as defined in claim 1); and 3) X.sup.9C.sub.1-5alkylR.sup.33 (wherein X.sup.9 represents --O--, --S--, --SO.sub.2--, --NR.sup.60CO--NR.sup.61SO.sub.2-- or --NR.sup.62-- (wherein R.sup.60, R.sup.61 and R.sup.62 each independently .[.represent.]. .Iadd.represents .Iaddend.hydrogen, C.sub.1-3alkyl or C.sub.1-3alkoxyC.sub.2-3alkyl) and R.sup.33 is as defined in claim 1); the reaction of a compound of the formula X: ##STR00038## (wherein X.sup.1, R.sup.1, R.sup.2, R.sup.3 and m are as defined in claim 1, L.sup.1 is as defined herein and R.sup.63 is C.sub.1-5alkyl) with a compound of the formula XI: R.sup.53--H (XI) (wherein R.sup.53 is as defined herein) to give a compound of the formula I; (f) for the preparation of compounds of the formula I wherein R.sup.4 is C.sub.2-5alkylR.sup.45, (wherein R.sup.45 is a group selected from imidazolidin-1-yl, pyrrolidin-1-yl and thiomorpholino, which group may bear one or two substituents selected from oxo, hydroxy, halogeno, C.sub.1-4alkyl, C.sub.1-4hydroxyalkyl, C.sub.1-4alkoxy, carbamoyl, C.sub.1-4alkylcarbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, C.sub.1-4alkanoyl and C.sub.1-4alkoxycarbonyl), the reaction of a compound of formula X (wherein R.sup.63 is C.sub.2-5alkyl) with a compound of the formula XIa: R.sup.45--H (XIa) (wherein R.sup.45 is as defined herein) to give a compound of the formula I; (g) for the preparation of those compounds of the formula I and salts thereof wherein the substituent R.sup.1 is represented by --NR.sup.5R.sup.6 where one or both of R.sup.5 and R.sup.6 are C.sub.1-3alkyl, the reaction of compounds of formula I wherein the substituent R.sup.1 is an amino group with an alkylating agent; (h) for the prepation of compounds of formula I and salts thereof wherein one or more of the substituents R.sup.1, R.sup.2 or R.sup.3 is an amino group, the reduction of a corresponding compound .[.of formula I.]. wherein the substituent(s) at the corresponding position(s) of the quinazoline and/or aniline ring is/are a nitro group(s): and when a pharmaceutically acceptable salt of a quinazoline derivative of formula I is required, reaction of the compound obtained with an acid or base whereby to obtain the desired pharmaceutically acceptable salt.

22. A pharmaceutical composition which comprises as active ingredient a compound of formula I as defined in .[.any one of claims 1 and 7-11.]. .Iadd.claim 1 or claim 7 .Iaddend.or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

.[.23. A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 and 7-11..].
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc